FTC's suit to block Amgen's purchase of Horizon Therapeutics set for Sept. 11 trial
JHVEPhoto/iStock Editorial via Getty Images

The Federal Trade Commission lawsuit to block Amgen's (NASDAQ:AMGN) planned purchase of Horizon Therapeutics (NASDAQ:HZNP) is set for a hearing on Sept. 11.
The trial date was set at a case management hearing in front of U.S. District Judge John Kness in Chicago on Tuesday.

The judge said he would likely take about four weeks after the hearing ends to make a ruling, according to a Reuters report. 

On Thursday, Amgen (AMGN) agreed not to close its $28 billion purchase of Horizon (HZNP) before Sept. 15 or the second business day after the court rules on the Federal Trade Commission's request to block the deal.

Horizon (HZNP) expects that its planned sale to Amgen (AMGN) can close by the end of Q3 or early in Q4 if the FTC's request for a preliminary injunction is denied by the federal court, according to an 8-K filing.